Clinical trial / 2019
Nicotinamide riboside supplementation for 12 weeks did not improve endocrine pancreatic function or incretin hormones in nondiabetic men with obesity.
A 12-week randomized, double-blind, placebo-controlled trial evaluated the effects of nicotinamide riboside (NR; 1000 mg twice daily, n = 20) versus placebo (n = 20) in 40 males with obesity and insulin resistance. Supplementation with NR did not affect fasting or postchallenge levels of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Furthermore, no changes in circulating adipsin or bile acids were observed.
- Study type
- 12-week randomized, double-blind, placebo-controlled parallel-group trial
- Who was studied
- 40 males with obesity and insulin resistance
- What was measured
- β-cell and α-cell function, incretin hormones (GLP-1, GIP), glucose, insulin, C-peptide, adipsin, and bile acids
THE PAPER
Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity.
Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Møller N, Gillum MP, Treebak JT, Jessen N. J Clin Endocrinol Metab, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.